Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

被引:0
|
作者
Y Tokuda
T Watanabe
Y Omuro
M Ando
N Katsumata
A Okumura
M Ohta
H Fujii
Y Sasaki
T Niwa
T Tajima
机构
[1] Tokai University School of Medicine,Department of Surgery
[2] Bohseidai,undefined
[3] National Cancer Center Hospital,undefined
[4] National Cancer Center Hospital East,undefined
[5] Mitsubishi Chemical Corporation,undefined
[6] Yokohama Research Center,undefined
来源
British Journal of Cancer | 1999年 / 81卷
关键词
HER2/; humanized monoclonal antibody; pharmacokinetics; phase I study;
D O I
暂无
中图分类号
学科分类号
摘要
We conducted a phase I pharmacokinetic dose escalation study of a recombinant humanized anti-p185HER2 monoclonal antibody (MKC-454) in 18 patients with metastatic breast cancer refractory to chemotherapy. Three or six patients at each dose level received 1, 2, 4 and 8 mg kg–1 of MKC-454 as 90-min intravenous infusions. The first dose was followed in 3 weeks by nine weekly doses. Target trough serum concentration has been set at 10 μg ml–1 based on in vitro observations. The mean value of minimum trough serum concentrations at each dose level were 3.58 ± 0.63, 6.53 ± 5.26, 40.2 ± 7.12 and 87.9 ± 23.5 μg ml–1 respectively. At 2 mg kg–1, although minimum trough serum concentrations were lower than the target trough concentration with a wide range of variation, trough concentrations increased and exceeded the target concentration, as administrations were repeated weekly. Finally 2 mg kg–1 was considered to be sufficient to achieve the target trough concentration by the weekly dosing regimen. One patient receiving 1 mg kg–1 had grade 3 fever, one at the 1 mg kg–1 level had severe fatigue defined as grade 3, and one at 8 mg kg–1 had severe bone pain of grade 3. No antibodies against MKC-454 were detected in any patients. Objective tumour responses were observed in two patients; one receiving 4 mg kg–1 had a partial response in lung metastases and the other receiving 8 mg kg–1 had a complete response in soft tissue metastases. These results indicate that MKC-454 is well tolerated and effective in patients with refractory metastatic breast cancers overexpressing the HER2 proto-oncogene. Further evaluation of this agent with 2–4 mg kg–1 weekly intravenous infusion is warranted.
引用
收藏
页码:1419 / 1425
页数:6
相关论文
共 50 条
  • [1] Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Tokuda, Y
    Watanabe, T
    Omuro, Y
    Ando, M
    Katsumata, N
    Okumura, A
    Ohta, M
    Fujii, H
    Sasaki, Y
    Niwa, T
    Tajima, T
    BRITISH JOURNAL OF CANCER, 1999, 81 (08) : 1419 - 1425
  • [2] A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody
    Ohta, M
    Tokuda, Y
    Suzuki, Y
    Kubota, M
    Watanabe, T
    Fujii, H
    Sasaki, Y
    Niwa, T
    Makuuchi, H
    Tajima, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (11) : 553 - 556
  • [3] Proteomic characterization of Her2/neu-overexpressing breast cancer cells
    Chen, Hexin
    Pimienta, Genaro
    Gu, Yiben
    Sun, Xu
    Hu, Jianjun
    Kim, Min-Sik
    Chaerkady, Raghothama
    Gucek, Marjan
    Cole, Robert N.
    Sukumar, Saraswati
    Pandey, Akhilesh
    PROTEOMICS, 2010, 10 (21) : 3800 - 3810
  • [4] Pathological evaluation of HER2 overexpression: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab)
    Umemura, S
    Sekido, Y
    Itoh, H
    Osamura, RY
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (02) : 77 - 81
  • [5] Proteomic characterization of Her2/neu-overexpressing breast cancer cells
    Chen, Hexin
    Pimienta, Genaro
    Gu, Yiben
    Sun, Xu
    Hu, Jianjun
    Kim, Min-Sik
    Chaerkady, Raghothama
    Gucek, Marjan
    Cole, Robert N.
    Sukumar, Saraswati
    Pandey, Akhilesh
    PROTEOMICS CLINICAL APPLICATIONS, 2011, 5 (3-4) : 201 - 201
  • [7] Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan
    Yutaka Tokuda
    Yasuhiro Suzuki
    Masatoshi Ohta
    Yuki Saito
    Mitsuhiro Kubota
    Tomoo Tajima
    Shinobu Umemura
    R. Yoshiyuki Osamura
    Breast Cancer, 2001, 8 (4) : 310 - 315
  • [8] Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)
    Shinobu Umemura
    Goi Sakamoto
    Hironobu Sasano
    Hitoshi Tsuda
    Futoshi Akiyama
    Masafumi Kurosumi
    Yutaka Tokuda
    Toru Watanabe
    Masakazu Toi
    Tadashi Hasegawa
    R. Yoshiyuki Osamura
    Breast Cancer, 2001, 8 (4) : 316 - 320
  • [9] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [10] A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel
    Kunitomo, K
    Inoue, S
    Ichihara, F
    Kono, K
    Fujii, H
    Matsumoto, Y
    Ooi, A
    HUMAN PATHOLOGY, 2004, 35 (03) : 379 - 381